Paper Details

  1. Home
  2. Paper Details

Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).

Author: AltenhoferJulia, CrispinAlexander, ParhoferKlaus G, RiksIna, VogtAnja, WaldmannElisa

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This phase II trial found that mipomersen reduced LDL-cholesterol significantly in patients on maximal lipid-lowering drug therapy and regular apheresis, but is often associated with side effects.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND AIMS: In this study, we evaluated the effect of mipomersen in patients with severe LDL-hypercholesterolaemia and atherosclerosis, treated by lipid lowering drugs and regular lipoprotein apheresis. METHODS: This prospective, randomized, controlled phase II single center trial enrolled...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.atherosclerosis.2017.02.019

データ提供：米国国立医学図書館（NLM）

Mipomersen: A Potential Weapon Against Severe LDL Hypercholesterolaemia

The battle against [severe LDL hypercholesterolaemia] is a challenging one, especially in patients who are resistant to conventional lipid-lowering therapies. This research explores the effectiveness of mipomersen, a novel treatment, in patients with severe LDL hypercholesterolaemia and atherosclerosis who are already undergoing [lipoprotein apheresis]. The study involved [15 patients] who were randomly assigned to receive either mipomersen or a placebo for 26 weeks. The researchers measured LDL-cholesterol levels, lipoprotein(a) (Lp(a)) concentrations, and a variety of other parameters.

Mipomersen: A Promising Addition to the Treatment Arsenal

The study found that mipomersen significantly reduced LDL-cholesterol levels in patients who received the treatment for more than 12 weeks. While mipomersen also decreased Lp(a) concentrations, the reduction was not statistically significant. The researchers noted that mipomersen was often associated with side effects, including injection site reactions and elevated liver enzymes. This underscores the need for careful monitoring and individualised treatment approaches when using mipomersen. This study demonstrates that mipomersen can be a valuable tool for managing severe LDL hypercholesterolaemia, but it's important to carefully weigh the potential benefits and risks for each individual patient.

Navigating the Treatment Landscape for High Cholesterol

This research provides valuable insights into the potential role of mipomersen in the management of severe LDL hypercholesterolaemia. Always consult with a healthcare professional to discuss the potential risks and benefits of mipomersen and to determine if it's the right treatment option for you.

Dr.Camel's Conclusion

This research provides a glimpse into the potential of mipomersen as a treatment for severe LDL hypercholesterolaemia. While mipomersen shows promise, it's important to be aware of its potential side effects and to work closely with a healthcare professional to make informed decisions about treatment. Just as a camel needs to navigate the desert's challenges, individuals with high cholesterol require personalized treatment strategies to achieve optimal health outcomes.

Date :
  1. Date Completed 2017-11-20
  2. Date Revised 2019-07-10
Further Info :

Pubmed ID

28279833

DOI: Digital Object Identifier

10.1016/j.atherosclerosis.2017.02.019

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.